The COVID-19 pandemic has left many of us with serious medical conditions, like coronary failure , feeling fearful about coming into the hospital for treatment. A recent study showed a 40 percent drop by patients seeking medical aid for serious heart attacks over the previous couple of months. If left unaddressed, the condition may become coronary failure , which can limit treatment options even further. Doctors are urging patients to not delay treatment.The good news is that clinical trials for heart condition are underway, studying cutting-edge treatments for coronary failure which will be an honest option for these patients.One such treatment being studied uses a patient’s own cells to market healing of the guts after a attack that has progressed to coronary failure . The CardiAMP cell therapy is meant for patients affected by coronary failure who feel tired and breathless despite taking regular medications, and who have had to limit their everyday activities as a result.Previously published studies of this sort of cell therapy have shown meaningful and sustained improvements in quality of life and heart function for patients with few risks."Heart failure patients who still have symptoms despite a course of optimal medications often seek a minimally invasive treatment as an alternate to open operation . we glance forward to studying the potential of this cell therapy to enhance heart function and quality of life," said Dr. Natasha Altman, cardiologist and PI of the CardiAMP coronary failure Trial at UC Health University of Colorado Hospital.For the treatment, doctors extract cells from a patient’s own bone marrow, process them at the purpose of care and deliver them to the damaged area of the guts during a minimally invasive cardiac catheterization procedure. Researchers emphasize that the bone marrow cells don't become new heart tissue cells; instead, they're designed to stimulate the body’s natural healing process within the heart.Pete Hagerstrom, a 73-year-old from Colorado Springs who had a previous quadruple bypass to treat his coronary failure , was the primary patient in his state enrolled within the ongoing FDA-approved clinical study of the therapy.Participants who qualify for the study are randomly placed into a treatment group or an impact group. While Mr. Hagerstrom won't know until the top of the study if he received the cell therapy, he feels better after participating within the trial."Everything is simpler . I can walk three miles in about 45 minutes, and it takes tons less time to garden and shovel snow."The CardiAMP coronary failure Trial will include up to 260 patients at 40 medical centers nationwide.Unlike similar studies, this trial tests a patient’s bone marrow before treatment, so as to spot those patients who are presumably to profit from treatment.Patients could also be candidates for the CardiAMP coronary failure Trial if they need coronary failure as a results of an earlier attack and have symptoms that are classified as ny Heart Association Class II or III.For more information about the CardiAMP coronary failure trial, visit www.biocardia.com, www.clinicaltrials.gov/ct2/show/NCT02438306, or ask your cardiologist.
